Lexicon Pharmaceuticals (LXRX) shares have edged lower in pre-market trading today after the company announced that the FDA needs more time to review its New Drug Application (NDA) for telotristat etiprate for the treatment of carcinoid syndrome. Its action date has been extended 90 days to February 28, 2017 from November 30, 2016. Per the agency's request, the company submitted additional analyses of the clinical data which will require additional time to review.